SERTAD1 (SERTA domain containing 1) is a multifunctional transcriptional coregulator that plays critical roles in cell cycle regulation, immune signaling, and disease pathogenesis. As a transcriptional coactivator, SERTAD1 enhances E2F1/TFDP1 transcriptional activity and renders cyclin D1/CDK4 activity resistant to CDKN2A/p16INK4A inhibition 1. The protein functions through direct protein-protein interactions, binding to the androgen receptor ligand-binding domain in prostate cancer cells 1 and interacting with enhancer factors CBP/p300 and RNA polymerase II-associated PAF1 complex to promote transcriptional activity 2. In immune regulation, SERTAD1 acts as an adaptor protein that restricts NLRP3 polyubiquitination, thereby facilitating inflammasome activation and cytokine secretion 3. The protein shows significant disease relevance, being upregulated in multiple pathological conditions including prostate cancer where it correlates with Gleason scores 1, multiple myeloma where chemotherapy induces its expression leading to PD-L1 upregulation and immune evasion 2, and Alzheimer's disease where it promotes aberrant autophagy and neuronal death 4. SERTAD1 also antagonizes p53 function by sequestering iASPP in the cytoplasm, preventing its nuclear translocation in leukemic cells 5. These diverse functions make SERTAD1 a potential therapeutic target across multiple diseases.